We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+25.02%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$336M
AUM Growth
+$9.25M
(+2.8%)
Cap. Flow
-$40.5M
Cap. Flow
% of AUM
-12.03%
Top 10 Holdings %
Top 10 Hldgs %
39.7%
Holding
90
New
18
Increased
16
Reduced
19
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Healthcare
ACHC
|
+$9.77M |
| 2 |
Elevance Health
ELV
|
+$8.59M |
| 3 |
Becton Dickinson
BDX
|
+$7.65M |
| 4 |
Eli Lilly
LLY
|
+$7.47M |
| 5 |
AbbVie
ABBV
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$10.8M |
| 2 |
Merck
MRK
|
+$8.29M |
| 3 |
Zimmer Biomet
ZBH
|
+$6.81M |
| 4 |
Denali Therapeutics
DNLI
|
+$6.5M |
| 5 |
Sanofi
SNY
|
+$6.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.04% |
| 2 | Energy | 4.31% |
| 3 | Financials | 0.52% |
| 4 | Consumer Discretionary | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Insmed
INSM
$29B
| $1.67M | 0.5% |
50,000
+25,000
| +100% | +$913K |
|
52
Karyopharm Therapeutics
KPTI
$47.6M
| $1.55M | 0.46% |
6,667
-5,000
| -43% | -$1.16M |
|
|
MYOV
53
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.38M | 0.41% |
50,000
| – | – |
|
|
BHVN
54
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.29M | 0.38% |
+15,000
| New | +$1.27M |
|
55
Precision BioSciences
DTIL
$207M
| $1.17M | 0.35% |
4,667
-5,333
| -53% | -$1.31M |
|
56
Lexicon Pharmaceuticals
LXRX
$1.08B
| $1.03M | 0.31% |
+300,000
| New | +$572K |
|
|
ITCI
57
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $954K | 0.28% |
30,000
-70,000
| -70% | -$1.84M |
|
|
APLS
58
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-90,000
| Closed | -$2.71M |
|
59
Baxter International
BAX
$14.3B
| – | – |
-40,000
| Closed | -$3.22M |
|
60
Bausch Health
BHC
$2.33B
| – | – |
-175,000
| Closed | -$2.72M |
|
61
Bristol-Myers Squibb
BMY
$130B
| – | – |
-50,000
| Closed | -$3.02M |
|
62
Chewy
CHWY
$9.2B
| – | – |
-35,000
| Closed | -$1.92M |
|
63
Centene
CNC
$32.1B
| – | – |
-95,000
| Closed | -$5.54M |
|
64
CALL
Cytokinetics
CYTK
$10.6B
| – | – |
-200,000
| Closed | -$4.33M |
|
65
DexCom
DXCM
$33.8B
| – | – |
-24,000
| Closed | -$2.47M |
|
66
Edwards Lifesciences
EW
$54B
| – | – |
-30,000
| Closed | -$2.4M |
|
67
Fate Therapeutics
FATE
$319M
| – | – |
-85,000
| Closed | -$3.4M |
|
68
Glaukos
GKOS
$10.7B
| – | – |
-40,000
| Closed | -$1.98M |
|
69
Genmab
GMAB
$19.2B
| – | – |
-30,000
| Closed | -$1.1M |
|
70
CALL
Gossamer Bio
GOSS
$88.9M
| – | – |
-100,000
| Closed | -$1.24M |
|
|
71
Gossamer Bio
GOSS
$88.9M
| – | – |
-200,000
| Closed | -$2.48M |
|
72
Halozyme
HALO
$11.6B
| – | – |
-155,000
| Closed | -$4.07M |
|
|
HOLX
73
DELISTED
Hologic
HOLX
| – | – |
-55,000
| Closed | -$3.66M |
|
|
74
Humana
HUM
$44.8B
| – | – |
-26,000
| Closed | -$10.8M |
|
75
PUT
Inovio Pharmaceuticals
INO
$79.1M
| – | – |
-8,333
| Closed | -$1.16M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Integral Health Asset Management held 90 positions worth $336M, up 2.8% from $327M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Integral Health Asset Management withdrew a net $40.5M in Q4 2020, closing 33 positions and reducing 19 holdings. Its most notable exit was Humana, an estimated $10.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier, followed by Energy and Financials.
Against the trend, Integral Health Asset Management opened a new position in Elevance Health worth $8.99M.
- Integral Health Asset Management's largest Q4 2020 buy was Elevance Health: 28,000 shares worth $8.99M.
- Integral Health Asset Management added most to Acadia Healthcare in Q4 2020, an estimated $9.77M increase.
- Integral Health Asset Management's biggest Q4 2020 reduction was Denali Therapeutics, cutting an estimated $6.5M.
- Integral Health Asset Management fully exited Humana in Q4 2020, selling an estimated $10.8M.
- Integral Health Asset Management's ten largest holdings make up 40% of its $336M portfolio in Q4 2020.
- Integral Health Asset Management opened 18 new positions and closed 33 in Q4 2020.
- Integral Health Asset Management's portfolio value rose 2.8% quarter-over-quarter to $336M.
Based on Integral Health Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.